•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
Biogen Inc. $BIIB Stock: Allspring Global Investments Holdings LLC Boosts Holdings
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's Disease
Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs
Biogen Inc. $BIIB Stock: Alpha Family Trust Boosts Holdings
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Biogen Q3 Earnings Call Highlights
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Big Day for Econ Data, Hyperscaler Earnings
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
Biogen Swings to Loss, Logs Higher Sales
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Baron Health Care Fund: Q3 2026 New Positions And Exits
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?